Table of Contents 1 399

ATS 2019 Virtual Final Program

COVER 1
WELCOME TO ATS 2019 3
OFFICERS 4
TABLE OF CONTENTS 5
FRIDAY, MAY 17 7
PG1A CRITICAL CARE ULTRASOUND AND ECHOCARDIOGRAPHY I 7
PG2 ECMO FOR EXPERIENCED PROVIDERS 8
PG3 A RESEARCHER’S GUIDE TO INTEGRATING THE PULMONARY ‘OMICSVERSE 9
PG4 FUNDAMENTALS OF WRITING SUCCESSFUL MENTORED CLINICAL RESEARCH GRANTS (FUND ME) 9
PG5 THORACIC IMAGING FOR PULMONARY MEDICINE AND CRITICAL CARE PRACTITIONERS 10
PG6 INTERSTITIAL LUNG DISEASE: CURRENT TRENDS IN DIAGNOSIS AND MANAGEMENT 11
PG7 ADVANCING CARE OF SICKLE CELL LUNG DISEASE: A PRACTICAL GUIDE TO PATIENT MANAGEMENT 12
PG8 PROCEEDINGS FROM THE WORLD SYMPOSIUM 2018: WHAT DO WE NEED TO KNOW MOVING FORWARD? 13
PG9 FUNCTIONAL ASSESSMENTS IN LUNG DISEASE: STRENGTH, ACTIVITY AND CARDIOPULMONARY EXERCISE TESTING WITH CASE CONFERENCE 14
PG10 RESPIRATORY PHYSIOLOGY INTERACTIVE 15
PG11 CARDIOMETABOLIC OUTCOMES OF OBSTRUCTIVE SLEEP APNEA TREATMENT: FROM EVIDENCE INTO PRACTICE 15
PG12 STATE OF THE ART: LUNG CANCER 2019 16
SATURDAY. MAY 18 18
PG1B CRITICAL CARE ULTRASOUND AND ECHOCARDIOGRAPHY II 18
PG13 BRONCH DAY 2019: A COMPREHENSIVE, HANDS-ON GUIDE TO BASIC BRONCHOSCOPY, EBUS, AND NAVIGATIONAL BRONCHOSCOPY 19
PG14 ASTHMA STATE OF THE ART 2019 20
PG15 A CLINICIAN’S GUIDE TO LUNG TRANSPLANTATION 21
PG16 INTERSTITIAL LUNG DISEASE: DELIVERING OPTIMAL, PATIENT CENTERED CARE 21
PG17 A PHYSIOLOGIC APPROACH TO MANAGEMENT OF SHOCK 22
PG18 TEACHING AND RESEARCHING IN RESOURCE CONSTRAINED SETTINGS: A GUIDE TO GLOBAL PULMONARY CRITICAL CARE MEDICINE 23
PG19 RESPIRATORY PHYSIOLOGY OVER THE LIFESPAN: WHEN IT’S RIGHT AND WHEN IT’S NOT 24
PG20 OPTIMIZING MANAGEMENT OF THE PATIENT WITH SEVERE BRONCHOPULMONARY DYSPLASIA 24
PG21 LUNG INNATE IMMUNITY: ON THE FRONTLINES OF HOST DEFENSE 25
PG22 ALL THINGS NTM: A ROAD MAP TO THE DIAGNOSIS AND MANAGEMENT OF NONTUBERCULOUS MYCOBACTERIA 26
PG23 HIGH-CONTENT SINGLE-CELL TECHNIQUES TO STUDY LUNG IN HEALTH AND DISEASE 27
PG24 PULMONARY FUNCTION TESTING IN THE REAL WORLD: 2019 UPDATES ON THE ART AND SCIENCE OF PFT 27
PG25 VENTILATORY COMPLICATIONS OF HEART FAILURE 28
OPENING CEREMONY 29
THE NETWORKING EXCHANGEFOR EARLY CAREER PROFESSIONALS 29
SUNDAY, MAY 19 30
SUNDAY MORNING, MAY 18 30
PCC1 PEDIATRIC CLINICAL CORE CURRICULUM 30
K1 WHEN EXPERTS DISAGREE: THE ART OF MEDICAL DECISION MAKING 30
K2 IMPLEMENTATION SCIENCE: HOW CAN IT SUPPORT HEALTH RESEARCH? 30
A1 CLINICAL YEAR IN REVIEW 1 30
A2 THE NEW ENGLAND JOURNAL OF MEDICINE AND JAMA. DISCUSSION ON THE EDGE: REPORTS OF RECENTLY PUBLISHED PULMONARY RESEARCH 31
A3 WHEN THERE IS NO RIGHT ANSWER: A PRO/CON DEBATE ON CONTROVERSIES IN ILD 31
A4 DO I HAVE TO? RE-EVALUATING COMMON PRACTICES IN THE ICU 32
A5 CELL FATE DETERMINATION IN THE LUNG IN HEALTH AND DISEASE: LOCATION AND NEIGHBORS MATTER 32
A6 PAP FOR ALL OR PAP FOR FEW: CONTROVERSIES IN MANAGEMENT OF SLEEP-DISORDERED BREATHING 33
A7 BREAKING THE PARADIGM: EARLY ORIGINS OF COPD 34
A8 CROSSING THE BORDER: MILDLY INCREASED PULMONARY ARTERY PRESSURE AND THE NEW DEFINITION OF PULMONARY HYPERTENSION 34
A9 NOVEL BIOMARKERS FOR THE DIAGNOSIS, PHENOTYPING, AND MANAGEMENT OF PEDIATRIC LUNG DISEASES 35
A10 TREATING ASTHMA IN PATIENTS WITH OBESITY: THE NEED FOR A NEW APPROACH 35
A11 CRITICAL CARE 2.0: INTEGRATING BIG DATA, CLINICAL TRIALS, AND IMPLEMENTATION SCIENCE TO CREATE A LEARNING ICU SYSTEM 36
A12 CAREGIVER BURDEN: BIDIRECTIONAL IMPACT OF PULMONARY, CRITICAL CARE, AND SLEEP DISORDERS ON THE ENTIRE FAMILY 36
A13 STATE OF THE ART TREATMENT OF TOBACCO DEPENDENCE 37
A14 REDUCING DISPARITIES AND IMPROVING OUTCOMES OF LUNG CANCER SCREENING 37
A15 CRITICAL CARE: BRAVE NEW WORLD - NEW INSIGHTS FROM CLINICAL TRIALS AND OBSERVATIONAL COHORTS 38
A16 CHEMICAL THREATS AND INJURY: MECHANISMS AND TREATMENT 38
A17 VIRAL INFECTION IN EARLY CHILDHOOD 39
A18 NTM: HOW, WHERE OR WHY DID I GET IT? 39
A19 LESS IDIOPATHIC: STRUCTURAL AND FUNCTIONAL ABNORMALITIES IN IPF 40
A21 ADVANCES IN ASTHMA PATHOGENESIS 40
A22 FACILITATING PALLIATIVE AND END-OF-LIFE CARE 41
A23 INTERVENTIONAL PULMONARY 42
A24 COPD: THERAPY, IMAGING, AND MOLECULAR MARKERS 43
A25 CRITICAL CARE: THE WIND IN THE WILLOWS - ARDS: OF SWINE AND MEN 44
A26 ENVIRONMENTAL MODIFIERS OF LUNG DISEASE 45
A27 PEDIATRIC LUNG INFECTION AND CRITICAL CARE AROUND THE WORLD 46
A28 BACTERIAL AND VIRAL LUNG INFECTIONS AND PATHOGENESIS 47
A29 EMERGING CONCEPTS IN LUNG FIBROSIS 48
A30 WHAT’S NEW IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE 50
A31 ASTHMA: CLINICAL STUDIES I 51
A32 ASTHMA: CLINICAL STUDIES II 52
A33 ADVANCES IN MEDICAL EDUCATION IN PULMONARY AND CRITICAL CARE MEDICINE 54
A34 SCREENING, DIAGNOSIS, AND TREATMENT IN SLEEP DISORDERS 55
A35 INTERVENTIONAL PULMONOLOGY 56
A36 RARE LUNG DISEASES FROM BENCH TO BEDSIDE 57
A37 CONNECTIVE TISSUE DISEASE-INTERSTITIAL LUNG DISEASE 58
A38 IDIOPATHIC INTERSTITIAL PNEUMONIA: DIAGNOSIS AND NATURAL HISTORY 59
A39 DRUG RELATED CASE REPORTS 60
A40 INFLAMMATORY DPLDs CASE REPORTS 61
A41 COPD: EPIDEMIOLOGY 63
A42 CRITICAL CARE: WHERE THE SIDEWALK ENDS - NONCONVENTIONAL VENTILATION, HFNC, NIV AND ECMO 65
A43 CRITICAL CARE: MAXIMUM OVERDRIVE - ACUTE RESPIRATORY FAILURE AND MECHANICAL VENTILATION 66
A44 CRITICAL CARE: ONE THOUSAND AND ONE NIGHTS - NON-PULMONARY CRITICAL CARE 67
A45 CRITICAL CARE: OF MICE AND MEN - INSIGHTS FROM EXPERIMENTAL AND ANIMAL MODELS IN ARDS AND SEPSIS 68
A46 CRITICAL CARE CASE REPORTS: ACID BASE, ELECTROLYTES, ENDOCRINE, METABOLIC AND RENAL 69
A47 CRITICAL CARE CASE REPORTS: MECHANICAL VENTILATION FROM NIV TO ECMO 70
A48 CRITICAL CARE CASE REPORTS: CAUSES AND COMPLICATIONS OF ACUTE RESPIRATORY FAILURE 71
A49 CASE REPORTS IN LUNG DISEASE ASSOCIATED WITH INHALATIONAL EXPOSURES 72
A50 MOLECULAR MECHANISMS OF ENVIRONMENTAL AND OCCUPATIONAL LUNG DISEASES 73
A51 PULMONARY HEALTH EFFECTS CAUSED BY OCCUPATIONAL EXPOSURES 74
A52 SARCOIDOSIS AND EXPOSURE RELATED INTERSTITIAL LUNG DISEASE 75
A53 CLINICAL STUDIES IN NEONATAL AND PEDIATRIC LUNG DISEASE AND CYSTIC FIBROSIS 76
A54 CASE REPORTS IN PULMONARY VASCULAR MEDICINE I 78
A55 PEDAL TO THE METAL: NEW INSIGHTS INTO ENDOTHELIAL RESPONSES TO LUNG INJURY 79
A56 SYMPATHY FOR THE CLOT: UPDATE ON PULMONARY EMBOLISM AND CTEPH 80
A57 NTM: CASE REPORTS 82
A58 NTM: EPIDEMIOLOGY AND CLINICAL STUDIES 83
A59 PULMONARY REHABILITATION: MUSCLE FUNCTION AND STRENGTH 83
A60 LUNG INJURY, SEPSIS, AND ARDS 84
A61 EPITHELIAL BIOLOGY 86
A62 MUCUS, MUCINS, MUCOCILIARY UNIT IN LUNG DISEASE 88
A63 PATHOPHYSIOLOGY OF ASTHMA IN CELLS, TISSUES, AND ANIMAL MODELS 89
A64 CLINICAL ASTHMA: ASSESSMENT AND TREATMENT 90
A65 OBESITY 91
A66 LYMPHANGIOLEIOMYOMATOSIS (LAM) 92
A67 ALTITUDE AND EXTREME ENVIRONMENT 92
A68 NEW TECHNIQUES, METHODOLOGIES, AND MATHEMATICAL MODELING 92
A69 SRN: WHAT CAN WE LEARN FROM CLINICAL AND EPIDEMIOLOGICAL STUDIES IN SLEEP? 94
A70 UNUSUAL PRESENTATIONS AND MIMICS: WHAT YOU SEE IS NOT ALWAYS WHAT YOU GET 95
A71 CASE REPORTS: WHEN IN DOUBT LOOK IN THE AIRWAY 96
A72 ADVANCES IN INTERVENTIONAL PULMONARY 96
SUNDAY MID-DAY, MAY 18 98
ATS DIVERSITY FORUM 98
WS1 TEACHING IN THE ICU PEARLS AND PITFALLS 98
WS2 ENHANCING GRANTSMANSHIP: UNDERSTANDING THE GRANT REVIEW PROCESS 99
CC1 EXPOSOMICS AND RESPONSOMICS IN ENVIRONMENTAL PULMONARY HEALTH 99
L1 EXPOSOMICS AND RESPONSOMICS IN ENVIRONMENTAL PULMONARY HEALTH 99
L2 PCORI: EVIDENCE TO ACTION NETWORKS: UPDATE OF PATIENT CENTERED OUTCOME RESEARCH RESULTS 100
L3 GENERIC DRUG DEVELOPMENT FOR RESPIRATORY PRODUCTS: U.S. FOOD AND DRUG ADMINISTRATION UPDATE 100
L4 NASA REMOTE SENSING SATELLITE OBSERVATIONS: APPLICATIONS FOR RESPIRATORY HEALTH 101
L5 RESULTS FROM NHLBI-FUNDED GENOMIC RESEARCH IN ALPHA-1 ANTITRYPSIN DEFICIENCY AND SARCOIDOSIS (GRADS) PROGRAM 101
L6 PREVENTION AND EARLY TREATMENT OF ACUTE LUNG INJURY (PETAL) CLINICAL TRIALS NETWORK 102
L7 ACCESS AND ANALYZE MASSIVE CLINICAL, IMAGE, AND GENOMICS DATA IN THE CLOUD 102
L8 MOLECULAR IMAGING OF THE LUNG (PHASE 2) 103
MEET THE PROFESSOR SEMINARS 103
ME1 HARNESSING THE POWER OF SOCIAL MEDIA AND FREE OPEN ACCESS MEDICAL EDUCATION (#FOAMED): AN INTERACTIVE WORKSHOP FOR MEDICAL EDUCATORS 104
SUNDAY AFTERNOON, MAY 18 104
A81 PEDIATRIC YEAR IN REVIEW 104
A82 CYSTIC FIBROSIS: HETEROGENEITY IN A MONOGENIC DISEASE 105
A83 GREAT CASES: CLINICAL, RADIOLOGIC, AND PATHOLOGIC CORRELATIONS BY MASTER PHYSICIANS 105
A84 JAMA AND THE NEW ENGLAND JOURNAL OF MEDICINE. DISCUSSION ON THE EDGE: REPORTS OF RECENTLY PUBLISHED CRITICAL CARE RESEARCH 106
A85 LIVING AND DYING BY LIPIDS: RESOLVING INFLAMMATION AND TEMPTING CELL FATE 106
A86 MECHANOPHARMACOLOGY OF AIRWAY AND AIRWAY SMOOTH MUSCLE 107
A87 KNOWLEDGE GAPS AND PATHWAYS FORWARD IN RV FAILURE RESEARCH: RECOMMENDATIONS FROM AN OFFICIAL ATS RESEARCH STATEMENT ON RV FAILURE 107
A88 RETHINKING OXYGEN: GETTING THE RIGHT OXYGEN TO THE RIGHT PATIENT 108
A89 COMMUNITY-ACQUIRED PNEUMONIA 2019: AN INTERACTIVE SESSION 108
A90 ICU-ACQUIRED WEAKNESS: A RAPID-FIRE DISCUSSION OF EMERGING ISSUES AND NEW INSIGHTS 109
A91 WHAT YOU CAN’T SEE MIGHT HURT YOU: THE INTERPLAY BETWEEN THE MICROBIOME AND IMMUNITY IN LUNG DISEASE 109
A92 HEALTH IMPACTS OF MARIJUANA: STATE OF THE SCIENCE AND FUTURE DIRECTIONS 110
A93 ASTHMA BREAKTHROUGHS: THE ROLE OF THE IMMUNE SYSTEM IN HUMAN ASTHMA 111
A94 INNOVATIONS TO IMPROVE CARE IN OBSTRUCTIVE LUNG DISEASE 111
A95 CRITICAL CARE: ALICE IN WONDERLAND - BIOMARKERS IN CRITICAL ILLNESS: CLUES TO BE UNRAVELLED 112
A96 NEW MECHANISMS OF OZONE TOXICITY 112
A97 STATION TO STATION: UNRAVELING THE MOLECULAR PATHOGENESIS OF PAH 112
A98 PHENOTYPING COPD AND PREDICTING THE DISEASE PROGRESSION 113
A101 TRANSLATIONAL STUDIES IN ILD, IPF, AND SARCOIDOSIS 113
A102 COPD: THERAPY 114
A103 CRITICAL CARE: AS YOU LIKE IT - ICU MANAGEMENT AND PROCESSES OF CARE 116
A104 WILDFIRE, BIOMASS, AND WORLD TRADE CENTER EXPOSURES 117
A105 GLORY DAYS: THE LATEST CLINICAL RESEARCH IN PAH 118
A106 NTM: BENCH TO BEDSIDE 119
A107 ENGINEERED AND REMODELLED MATRIX COMPARTMENTS 120
A108 PATHOPHYSIOLOGY IN DIFFUSE PARENCHYMAL LUNG DISEASES 121
A109 SRN: OSA PATHOPHYSIOLOGY AND TREATMENT - MOVING TOWARDS PERSONALIZED MEDICINE 122
A110 NOVEL IMAGING FOR LUNG CANCER: A PICTURE IS WORTH A THOUSAND WORDS 123
RESPIRATORY HEALTH AWARDS PRESENTATION OFTHE AMBERSON LECTURE, TRUDEAU MEDAL AND DISTINGUISHED ACHIEVEMENT AWARDS 125
ASSEMBLY ON PEDIATRICS MEMBERSHIP MEETING 125
FOUNDERS DINNER 125
SECTION ON GENETICS AND GENOMICS MEMBERSHIP MEETING 126
ASSEMBLY ON BEHAVIORAL SCIENCE AND HEALTH SERVICES RESEARCH MEMBERSHIP MEETING 126
STRATEGIES FOR TB CONTROL: POSTER SESSION 126
MONDAY, MAY 20 127
MONDAY, MORNING, MAY 20 127
PCC2 PEDIATRIC CLINICAL CORE CURRICULUM 127
SUNRISE SEMINARS 127
FD1 FACULTY PROMOTION AND TENURE: UNRAVELING THE “FACULTY HANDBOOK” 128
K3 DATA SHARING IN THE CONTEXT OF CLINICAL TRIALS 128
K4 UNRAVELLING THE MYSTERY OF BREATHLESSNESS IN COPD 128
B1 CLINICAL YEAR IN REVIEW 2 129
B2 ENDOBRONCHIAL VALVE TREATMENT IN PATIENTS WITH ADVANCED EMPHYSEMA: IT’S TIME HAS COME 129
B3 FELLOWS CASE CONFERENCE 130
B4 KEEPING MY CRITICALLY ILL PATIENT COMFORTABLE, AWAKE, ENGAGED, AND MOVING 130
B5 TILL DEATH DO US PART: CELL FATE AND OBSTRUCTIVE LUNG DISEASE 131
B6 BORN TOO SOON: THE EFFECTS OF PREMATURITY ON THE NEONATAL/DEVELOPING LUNG 131
B7 GLOBAL PERSPECTIVES ON CLIMATE CHANGE: IMPACT ON SUSCEPTIBLE POPULATIONS AND LOW-INCOME COUNTRIES 132
B8 ENSURING BROAD DISSEMINATION AND EQUITABLE ACCESS TO LUNG CANCER SCREENING: CHALLENGES AND OPPORTUNITIES 132
B9 ADDICTING A NEW GENERATION: JUULING, VAPING, HEAT NOT BURN, FLAVORINGS, AND THE EVIDENCE FOR WHY WE SHOULD BE VERY CONCERNED 133
B10 HUMAN LUNG CELL ATLAS: BEYOND SINGLE CELL RNA-SEQUENCING 133
B11 LUNG-OMICS: TO BOLDLY GO... 134
B12 HOT TOPICS IN MEDICAL EDUCATION: WHAT’S NEW IN ‘19 135
B13 50 YEARS OF PROGRESS IN PULMONARY SCIENCE 135
B14 LATE BREAKING CLINICAL TRIALS 136
B15 IMMUNOTHERAPY FOR LUNG DISEASE 136
B16 ADVANCES IN INTERVENTIONAL PULMONARY 137
B17 ADVANCES IN ILD THERAPY 137
B18 ENHANCING QUALITY OF LIFE AND DISEASE MANAGEMENT IN PULMONARY CONDITIONS 138
B19 ADVANCES IN THE TREATMENT OF NTM 138
B20 LUNG TRANSPLANTATION: MODELS AND MECHANISMS 139
B21 SEVERE ASTHMA: CLINICAL AND MECHANISTIC STUDIES 139
B22 CRITICAL ILLNESS MANAGEMENT AND OUTCOMES 140
B23 CRITICAL CARE: STEP ACROSS THIS LINE - MICROBIOME, GENETICS, AND OTHER BIOMARKERS IN ACUTE CRITICAL ILLNESS 141
B24 CRITICAL CARE: GONE WITH THE WIND - MECHANICAL VENTILATION: HFNC, NIV AND INVASIVE 143
B25 OCCUPATIONAL EXPOSURES INCLUDING DEPLOYMENT RELATED, MINING, AND AGRICULTURE 144
B26 CLINICAL STUDIES IN PEDIATRIC SLEEP, HOME VENTILATION AND NEUROMUSCULAR DISEASE 145
B27 HEARTBREAKER: HEART FAILURE AND PULMONARY HYPERTENSION 145
B28 HOW AIRWAYS MALFUNCTION: NEW CONCEPTS 147
B29 MECHANISMS FOR AIRWAY HYPERRESPONSIVENESS: FROM CELL TO ORGANISM 148
B30 SRN: BIG DATA ANALYSIS AND POPULATION BASED STUDIES 149
B31 LUNG TRANSPLANTATION: CLINICAL AND MECHANISTIC STUDIES 150
B32 ASTHMA: MECHANISMS OF DISEASE I 150
B33 ASTHMA: MECHANISMS OF DISEASE II 152
B34 ALLERGIC DISEASE: CLINICAL STUDIES AND MECHANISMS 153
B35 EPIDEMIOLOGICAL STUDIES AND MANAGEMENT OF COPD 154
B36 ADDICTION AND TOBACCO USE IN PULMONARY AND CRITICAL CARE MEDICINE 155
B37 NOVEL APPROACHES TO ASTHMA MANAGEMENT AND OUTCOMES 156
B38 LUNG CANCER: SCREENING PRACTICES AND TREATMENT OUTCOMES 157
B39 GRANULOMATOUS ILDs 158
B40 AUTOIMMUNE LUNG DISEASE CASE REPORTS 159
B41 INTERVENTIONAL PULMONOLOGY CASE REPORTS I 161
B42 DYSPNEA CASE REPORTS 162
B43 PLEURAL DISEASE CASE REPORTS I 164
B44 COPD: TREATMENT AND OTHER TOPICS 165
B45 COPD: TREATMENT 167
B46 IDIOPATHIC INTERSTITIAL PNEUMONIA: NATURAL HISTORY 169
B47 CRITICAL CARE: THE HEART GOES LAST - CARDIAC ARREST, CARDIAC SURGERY AND COMPLICATIONS OF THE HEART 171
B48 CRITICAL CARE: MEASURE FOR MEASURE - QUALITY IMPROVEMENT AND IMPLEMENTATION OF BEST PRACTICE 172
B49 CRITICAL CARE: EAST OF EDEN - PREDICTING AND MEASURING OUTCOMES 173
B50 CRITICAL CARE CASE REPORTS: CARDIOVASCULAR DISEASES IN THE ICU I 174
B51 CRITICAL CARE CASE REPORTS: CARDIOVASCULAR DISEASES IN THE ICU II 175
B52 CRITICAL CARE CASE REPORTS: THE LIVER, PANCREAS AND INTESTINES 176
B53 SLEEP DISORDERED BREATHING AND LONG-TERM VENTILATION IN PEDIATRICS 178
B54 CASE REPORTS IN PULMONARY VASCULAR MEDICINE II 178
B55 USE YOUR ILLUSION I: CLINICAL RESEARCH IN PAH 180
B56 LET’S GET PHYSICAL: EXERCISE AND BIOMECHANICS OF PAH 181
B57 CLINICAL STUDIES IN LUNG INFECTIONS: RISK FACTORS AND BIOMARKERS 182
B58 CLINICAL STUDIES IN LUNG INFECTIONS AND PNEUMONIA: TREATMENT AND OUTCOMES 183
B59 BACTERIAL INFECTION CASE REPORTS 183
B60 PULMONARY REHABILITATION: GENERAL 184
B61 COPD: BASIC DISCOVERY 185
B62 ASTHMA MECHANISMS 187
B63 ANIMAL MODELS OF COPD 189
B64 COPD: MECHANISM AND TREATMENT 189
B65 SRN: DIAGNOSIS AND MONITORING OF SLEEP AND SLEEP DISORDERS 191
B66 SRN: CURRENT AND EMERGING TREATMENT THERAPIES TO IMPROVE SLEEP 192
B67 CASE REPORTS: DIAGNOSTIC AND MANAGEMENT DILEMMAS 193
B68 ONCOGENIC MUTATIONS, METASTASIS, AND NOVEL THERAPEUTICS 194
B69 THORACIC ONCOLOGY: OPTIMIZING DIAGNOSIS AND MANAGEMENT 195
MONDAY, MID-DAY, MAY 20 197
ATS WOMEN’S FORUM 197
WS3 DEMYSTIFYING PEDIATRIC EXERCISE TESTING INTERPRETATION 197
WS4 PROMOTING WELLNESS IN HEALTH CARE TEAMS: A PRACTICAL APPROACH 197
CC2 SLEEP MEDICINE CLINICAL CORE CURRICULUM I 198
L12 MILLION VETERAN PROGRAM: OPPORTUNITIES FOR STUDY OF GENETIC CONTRIBUTIONS TO RESPIRATORY DISEASES 198
L13 UPDATE ON CLASSIFICATION OF CHEST RADIOGRAPHS AND THE B READER PROGRAM 199
L14 ASTHMA PREDICTION: NEW FINDINGS FROM COHORTS 199
L15 PULMONARY UPDATE FROM THE U.S. FOOD AND DRUG ADMINISTRATION 200
L16 THE COPD NATIONAL ACTION PLAN: 2019 UPDATE 200
L17 NHLBI MACS/WIHS COMBINED COHORT: A RESOURCE FOR APPLIED RESEARCH ON HIV-RELATED PULMONARY COMPLICATIONS 200
L18 RESIDENT DUTY HOURS, PATIENT SAFETY, AND RESIDENT SLEEP: RESULTS OF THE ROSTERS AND ICOMPARE TRIALS 201
L19 NICOTINE AND THE FDA PERSPECTIVE: REGULATION, SCIENCE, PATIENT EDUCATION, AND CLINICAL PRACTICE 201
MEET THE PROFESSOR SEMINARS 202
ME2 DESIGNING AN EFFECTIVE SIMULATION CURRICULUM 202
MONDAY AFTERNOON, MAY 20 203
PRESENTATION OF THE RECOGNITION AWARDS FOR SCIENTIFIC ACCOMPLISHMENTS 203
CC3 PULMONARY CLINICAL CORE CURRICULUM II. 203
B81 NURSING YEAR IN REVIEW: PATIENT AND FAMILY ENGAGEMENT 204
B82 PRO/CON: THE CONUNDRUM OF MANAGING ACUTE PULMONARY EMBOLISM 204
B83 MANAGEMENT OF NEUROMUSCULAR RESPIRATORY FAILURE SYNDROMES: NIPPV FOR DAY, NIGHT AND THE SOCCER FIELD 205
B84 CAN’T STOP OR WON’T STOP: THE ROLE OF CLINICAL INERTIA IN CRITICAL CARE MEDICINE 206
B85 THEY’VE GOT THE BEAT: CILIA IN DEVELOPMENT AND DISEASE 206
B86 PULMONARY REHABILITATION IN NON-COPD CHRONIC RESPIRATORY CONDITIONS 207
B87 CROSSTALK BETWEEN AIRWAY EPITHELIUM AND TYPE 2 IMMUNITY IN ASTHMA 207
B88 MIGRANT AND REFUGEE MEDICINE: IMPLICATIONS FOR PULMONARY AND CRITICAL CARE CLINICIANS 208
B89 CHALLENGES IN CONDUCTING AND INTERPRETING ARDS AND SEPSIS RANDOMIZED CLINICAL TRIALS 208
B90 BIG TOBACCO: LAWYERS, GUNS AND MONEY 209
B91 HAVE A BIGGER IMPACT! EFFECTIVE STRATEGIES TO UTILIZE YOUR PROFESSIONAL EXPERTISE TO ADVOCATE FOR YOUR PATIENTS AND YOUR COMMUNITIES 209
B92 ATS FAMILY OF JOURNALS IN 2019 210
B93 COPD: MORTALITY AND RISK PREDICTION 210
B94 BEST OF PEDIATRICS 211
B95 CELLULAR AND MOLECULAR LANDSCAPE OF THE LUNG 211
B96 COMPLEX CELL BEHAVIORS IN PULMONARY FIBROSIS 212
B97 SRN: UPPER AIRWAY PATHOPHYSIOLOGY AND TREATMENT IN SLEEP DISORDERED BREATHING 212
B98 TARGETING THE IMMUNE SYSTEM IN LUNG CANCER PROGRESSION 212
B101 ADVANCES IN COPD PATHOGENESIS 213
B102 DISPARITIES IN ASTHMA MANAGEMENT 214
B103 ILD: THERAPY 215
B104 CRITICAL CARE: CATCH-22 - BEYOND THE VENTILATOR: THE CHALLENGES OF DELIRIUM, ICU-ACQUIRED WEAKNESS, AND REHABILITATION 216
B105 CRITICAL CARE: COUNTERPARTS - NON-PULMONARY CRITICAL CARE AND MULTI-ORGAN FAILURE 217
B106 CRITICAL CARE: A HUNDRED YEARS OF SOLITUDE - CARING FOR THE VULNERABLE: PATIENT, FAMILY, AND HCP-CENTERED CARE 218
B107 EFFECTS OF E-CIGARETTES AND THEIR COMPONENTS ON RESPIRATORY DYSFUNCTION, INFLAMMATION, AND REPAIR 219
B108 UNDER PRESSURE: THE ROLE OF CELLULAR STRESS IN PULMONARY VASCULAR REMODELING 220
B109 WHAT’S NEW WITH CLINICAL LUNG INFECTIONS AND PNEUMONIA? 221
B110 MYCOBACTERIAL HOST DEFENSE AND PATHOGENESIS 222
ASSEMBLY MEMBERSHIP MEETINGS 224
TUESDAY, MAY 21 225
TUESDAY MORNING, MAY 21 225
PCC3 PEDIATRIC CLINICAL CORE CURRICULUM 225
SUNRISE SEMINARS 225
FD2 USING DIGITAL SCHOLARSHIP STRATEGICALLY FOR CAREER ADVANCEMENT 226
K5 DEVELOPING THE EVIDENCE FOR VALUE BASED CARE IN PULMONARY MEDICINE 226
K6 ENHANCING DIVERSITY AND INCLUSION IN ACADEMIC MEDICINE 226
C1 CLINICAL YEAR IN REVIEW 3 227
C2 CLOSING THE EVIDENCE GAP IN LUNG DISEASE WITH REAL WORLD DATA 227
C3 EVIDENCE IN ASTHMA COPD OVERLAP: CLINICAL AND MOLECULAR STUDIES TO ADVANCE TREATMENT 228
C4 WHEN THE SUN SETS: NIGHTTIME IN THE ICU 228
C5 DISCOVERING THE ROLE OF STEM CELL FATE IN LUNG INJURY AND FIBROSIS 229
C6 THE FORGOTTEN CELL: RED BLOOD CELLS AS MODULATORS OF IMMUNITY 229
C7 WHAT PULMONOLOGISTS NEED TO KNOW ABOUT CANCER IMMUNOTHERAPY 230
C8 BRONCHIECTASIS: MOVING BEYOND THE VICIOUS CYCLE 230
C9 DIFFICULT TO TREAT ASTHMA IN THE PEDIATRIC POPULATION 231
C10 LIFESPAN WEIGHT MANAGEMENT OF SLEEP DISORDERS: REAL, FEASIBLE OR JUST THEORY? 231
C11 FUTURE DIRECTIONS IN PAH RESEARCH: A PRO/CON DEBATE 232
C12 MACROPHAGES: LINEAGE, DIVERSITY, AND LUNG DISEASE 232
C13 CLIMATE CHANGE AND RESPIRATORY HEALTH: WIDENING U.S. DISPARITIES 233
C14 CRITICAL CARE: THE CRUCIBLE - OPTIMIZING MECHANICAL VENTILATION: INNOVATIVE TRIALS AND TOOLS 233
C15 OCCUPATIONAL EXPOSURES OF THE 21ST CENTURY 234
C16 CLINICAL STUDIES IN BRONCHOPULMONARY DYSPLASIA 234
C17 PULMONARY REHABILITATION 2019 235
C18 RARE LUNG DISEASES 235
C19 NEW PATHWAYS REGULATING AIRWAY SMOOTH MUSCLE CONTRACTION: POTENTIAL TARGETS FOR ASTHMA THERAPY 236
C21 DETERMINANTS OF BURNOUT AND WELLNESS AMONG PHYSICIANS AND TRAINEES 236
C22 ILD: DIAGNOSIS 237
C23 PLEURAL DISEASE, CF, AND OTHER MAGICAL CREATURES 238
C24 ENHANCING THE TREATMENT ENVIRONMENT TO IMPROVE PATIENT AND CAREGIVER OUTCOMES 239
C25 CLINICAL AND TRANSLATIONAL STUDIES IN RARE LUNG DISEASE 240
C26 LET IT BLEED: ENDOTHELIAL INJURY AND ANGIOGENESIS IN PULMONARY HYPERTENSION 241
C27 TB TREATMENT 242
C28 PATHWAYS OF LUNG MORPHOGENESIS 243
C29 SRN: FUNDAMENTALS IN SLEEP AND RESPIRATORY NEUROBIOLOGY 244
C30 LUNG CANCER SCREENING: LESSONS FROM THE FRONT-LINE 245
C31 TRANSLATIONAL STUDIES IN SARCOIDOSIS 246
C32 COPD: TRANSLATIONAL AND MECHANISTIC STUDIES 247
C33 CASE REPORTS IN AUTOIMMUNE AND INFLAMMATORY LUNG DISEASES 249
C34 ILD AND IPF: CLINICAL AND MECHANISTIC STUDIES 250
C35 HEALTH SERVICES RESEARCH IN COUGH, CF, AND ILD 251
C36 INTERVENTIONAL PULMONOLOGY CASE REPORTS II 252
C37 SYMPTOMS, PLEURAL DISEASE, BEHAVIORAL SCIENCE, AND OTHER TOPICS 254
C38 AUTOIMMUNE, DRUG RELATED, AND TRANSPLANT 255
C39 IDIOPATHIC INTERSTITIAL PNEUMONIA: THERAPY 257
C40 CRITICAL CARE: THE ART OF WAR - INNOVATIONS IN EDUCATION 258
C41 CRITICAL CARE CASE REPORTS: TOXICOLOGY AND POISONINGS 259
C42 CRITICAL CARE CASE REPORTS: TOXICOLOGY AND POISONINGS 2 260
C43 COPD AND POPULATION HEALTH 261
C44 ASTHMA EPIDEMIOLOGY 262
C45 EFFECTS OF THE ENVIRONMENT ON PULMONARY HEALTH 263
C46 CASE REPORTS: PEDIATRIC DIFFUSE LUNG DISEASE 264
C47 CASE REPORTS: PEDIATRIC CYSTIC FIBROSIS, LUNG INFECTION, AND SLEEP DISORDERED BREATHING 265
C48 CASE REPORTS: NEONATAL LUNG DISEASE, CONGENITAL MALFORMATIONS, AND MORE 266
C49 TICKET TO RIDE: EXPERIMENTAL MODELS OF PAH 268
C50 THE PERFECT DRUG: EXPERIMENTAL TREATMENTS OF PAH 269
C51 CLOSER TO THE HEART: UPDATE ON APPROVED THERAPIES FOR PAH 270
C52 USE YOUR ILLUSION II: CLINICAL RESEARCH IN PAH 271
C53 TUBERCULOSIS CASE REPORTS 272
C54 TUBERCULOSIS EPIDEMIOLOGY 273
C55 TUBERCULOSIS DIAGNOSIS 274
C56 HIV: CLINICAL STUDIES AND BASIC SCIENCE MODELS 275
C57 VIRAL LUNG INFECTION CLINICAL STUDIES AND CASE REPORTS 276
C58 MECHANISMS OF PULMONARY FIBROSIS 277
C59 GENETIC AND EPIGENETIC MECHANISMS IN PULMONARY FIBROSIS 279
C60 VASCULAR BIOLOGY IN LUNG DISEASE 280
C61 LUNG DEVELOPMENT, BPD, AND STEM CELLS 281
C62 FIBROBLAST BIOLOGY 282
C63 MECHANISTIC STUDIES IN COPD 283
C64 PULMONARY FIBROSIS MODELS AND MECHANISTIC INSIGHTS 286
C65 DIFFUSE PARENCHYMAL LUNG DISEASES: BASIC AND CLINICAL STUDIES 287
C66 MECHANICAL VENTILATION 288
C67 LUNG FUNCTION TEST 289
C68 SLEEP DISORDER 289
C69 LUNG CANCER 290
C70 NEONATAL AND PEDIATRIC LUNG DISEASE 290
C71 PULMONARY HYPERTENSION 291
C72 CASE REPORTS OF RARE DISEASES 292
C73 SRN: CURIOUS CASES IN SLEEP AND RESPIRATORY MEDICINE 292
C74 LUNG CANCER: BIOMARKERS FOR PROGNOSIS AND OUTCOMES 293
TUESDAY MID-DAY, MAY 21 294
ATS PLENARY SESSION 294
WS5 DESIGNING A COMPREHENSIVE CRITICAL CARE ULTRASOUND CURRICULUM 294
WS6 CANCELED: HEALTH POLICY ADVOCACY 101: EFFECTIVELY INFORM YOUR ELECTED OFFICIALS 295
MEET THE PROFESSOR SEMINARS 295
ME3 OPTIMIZING LEARNER-CENTERED EDUCATION IN THE AMBULATORY CLINIC 296
TUESDAY AFTERNOON, MAY 21 296
CC4 SLEEP MEDICINE CLINICAL CORE CURRICULUM II 296
C82 CHALLENGES IN THE LONG-TERM CLINICAL MANAGEMENT OF SARCOIDOSIS 297
C83 PEDIATRIC CLINICAL CHEST ROUNDS 297
C84 CLINICAL TRIALS IN THE CRITICALLY ILL: ECMO AS A CAUTIONARY TALE 298
C85 SCIENTIFIC BREAKTHROUGHS IN LUNG BIOLOGY 298
C86 LUNGMAP-ING CELL LINEAGES IN HUMAN DEVELOPMENT AND DISEASE 299
C87 PHYSIOLOGICALLY-GUIDED MECHANICAL VENTILATION 299
C88 COMPLEMENT AS A NOVEL TARGET TO MITIGATE LUNG DISEASE 300
C89 TRANSLATIONAL DEVELOPMENTS IN TB: TOWARDS IMPROVING PREVENTION AND MANAGEMENT STRATEGIES 300
C90 BENCH TO BEDSIDE: HOW DIETARY N3-PUFAS MODULATE THE PULMONARY RESPONSE TO ENVIRONMENTAL EXPOSURES 301
C91 IMPROVING CARE QUALITY WHILE REDUCING COST: IS HIGH VALUE CARE FOR COPD ACHIEVABLE? 301
C92 ATS CLINICAL PRACTICE GUIDELINES: CLINICAL PRACTICE ON THE CUTTING EDGE 302
C93 MECHANISMS OF AIRWAY INFLAMMATION IN ASTHMA AND COPD 302
C94 THE IMPACT OF SOCIAL DETERMINANTS IN PULMONARY AND CRITICAL CARE 303
C95 ENHANCING PATIENT-CENTERED CARE IN CRITICAL CARE 303
C96 COPD AND PLEURAL DISEASE 304
C97 DON’T STOP BELIEVING: CLINICAL TRIALS IN PULMONARY VASCULAR MEDICINE 304
C98 HOST RESPONSE TO LUNG INFECTIONS: INSIGHTS INTO NEW MECHANISMS 305
C99 SRN: CARDIOMETABOLIC CONSEQUENCES OF SLEEP DISORDERED BREATHING AND THE ROLE OF CPAP THERAPY 305
C101 NON-IDIOPATHIC INTERSTITIAL PNEUMONIA NATURAL HISTORY AND PROGNOSIS AND ILD THERAPY 306
C102 COPD: RISK PREDICTION AND PROGNOSIS 307
C103 CRITICAL CARE: THE LONG WALK - ELUCIDATING OUTCOMES: DEATH, FUNCTIONAL STATUS AND COGNITION 308
C104 THE MODERN PEDIATRIC PULMONARY FUNCTION LAB: NEW STANDARDS AND NEW TESTS 309
C105 BRONCHIECTASIS: FROM CLINICAL PHENOTYPES TO TREATMENT 310
C106 PULMONARY REHABILITATION 311
C107 GOING VIRAL TO REPAIR 312
C108 COPD: PHENOTYPE, MECHANISM, AND TREATMENT 313
C109 RESPIRATORY MUSCLE DYSFUNCTION: MECHANISM AND ASSESSMENT 314
C110 THE FUTURE OF LUNG CANCER BIOMARKERS: WHERE SHOULD WE LOOK? 315
WEDNESDAY, MAY 22 317
WEDNESDAY MORNING, MAY 22 317
PCC4 PEDIATRIC CLINICAL CORE CURRICULUM 317
SUNRISE SEMINARS 317
FD3 NEGOTIATING FOR YOUR FUTURE: SKILLS AND STRATEGIES FOR SUCCESS 318
K7 WHAT SHOULD PULMONOLOGISTS KNOW ABOUT ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING? 318
D1 CLINICAL YEAR IN REVIEW 4 318
D2 STATE OF THE ART PLEURAL DISEASE MANAGEMENT: CLINICAL TRIALS CHANGING CARE PRACTICE 319
D3 RURALITY IN COPD: DEFINING THE PROBLEM AND DEPLOYING NOVEL CARE DELIVERY APPROACHES 319
D4 BIG DATA AND CLINICAL TRIALS: FRIENDS, FOES, OR FRENEMIES? 320
D5 SLEEPING WITH THE ENEMY: EXPLORING THE IMPACT OF SLEEP DISORDERED BREATHING ON CANCER 320
D6 SITES FOR PULMONARY REHABILITATION: WHERE CAN AND SHOULD IT BE PERFORMED? 321
D7 EXOSOMES: WEAPONS OF MASS DESTRUCTION 321
D8 ENVIRONMENTAL EXPOSURES, THE HUMAN MICROBIOME, AND LUNG DISEASE 322
D9 HOST DIRECTED THERAPY FOR TUBERCULOSIS: THEORY AND CURRENT EVIDENCE 322
D10 BUILDING BLOCKS OF IMPLEMENTATION: HOW TO IMPLEMENT ICU EVIDENCE-BASED CARE 323
D11 ALL CELLS ON DECK: IMMUNE CELLS AND THE PATHOGENESIS OF LUNG INJURY 323
D12 ILD: DIAGNOSIS AND PROGNOSIS 324
D13 TRANSPLANTATION 324
D14 CRITICAL CARE: GREAT EXPECTATIONS - RECOVERY AND OUTCOMES AFTER CRITICAL ILLNESS 325
D15 THE BEST OF PEDIATRIC ASTHMA EPIDEMIOLOGY 325
D16 EVERY CELL YOU BREAK: HOW CELLULAR PHENOTYPES CONTRIBUTE TO PAH 326
D17 TOWARDS THE NEXT IPF THERAPIES 326
D18 BEST OF NOVEL TECHNOLOGIES AND METHODOLOGIES 327
D19 LUNG CANCER SCREENING: NOVEL INSIGHTS ON PATIENT SELECTION AND OUTCOMES 327
D21 HOST RESPONSE TO LUNG INFECTIONS 328
D22 REAL WORLD MEDICATION USE IN PULMONARY DISEASES 329
D23 COPD: DIAGNOSIS AND EPIDEMIOLOGY 330
D24 AUTOIMMUNE DISEASE, DRUG-INDUCED, AND TRANSPLANT 331
D25 CRITICAL CARE: HARD TIMES - RESUSCITATING MY PATIENT: FLUID, BLOOD AND OTHER STRATEGIES 332
D26 HEALTH EFFECTS ASSOCIATED WITH INDOOR AND OUTDOOR AIR POLLUTION 333
D27 MECHANISTIC INSIGHTS INTO BRONCHOPULMONARY DYSPLASIA 334
D28 CLOT ME A RIVER: LATEST DEVELOPMENTS IN DIAGNOSIS AND MANAGEMENT OF PULMONARY EMBOLISMS AND CTEPH 335
D29 LUNG MULTI-OMICS TO MECHANISM 336
D30 ASTHMA: WHAT’S NEW IN ASSESSMENT AND TREATMENT? 337
D31 ALLERGY AND ASTHMA CASE REPORTS 338
D32 ACUTE LUNG INJURY AND ARDS: CLINICAL AND MECHANISTIC STUDIES 339
D33 PATHOLOGIC MECHANISMS IN PULMONARY INFECTIONS 340
D34 CYSTIC FIBROSIS AND BRONCHIECTASIS: CLINICAL AND MECHANISTIC STUDIES 341
D35 TESTING, PROCEDURES, AND OUTCOMES IN PULMONARY AND CRITICAL CARE MEDICINE 342
D36 INNOVATIONS IN RESEARCH METHODS AND EVIDENCE SYNTHESIS 342
D37 TOPICS IN GLOBAL HEALTH SERVICES RESEARCH 343
D38 LUNG TRANSPLANTATION AND DRUG RELATED CASE REPORTS 344
D39 RARE DPLD CASE REPORTS 345
D40 NON-INFLAMMATORY DPLDs CASE REPORTS 347
D41 COUGH AND IMMUNODEFICIENCIES CASE REPORTS 348
D42 PLEURAL DISEASE CASE REPORTS II 349
D43 COPD, CF, AND BRONCHIECTASIS CASE REPORTS 350
D44 CRITICAL CARE: AN ENCOUNTER - HOW WE MANAGE CRITICAL CARE IN AND OUT OF THE ICU 351
D45 CRITICAL CARE: LOVE IN THE TIME OF CHOLERA - INFECTION AND SEPSIS IDENTIFICATION AND MANAGEMENT 352
D46 CRITICAL CARE CASE REPORTS: HEMATOLOGY, ONCOLOGY, RHEUMATOLOGY AND IMMUNOLOGY 353
D47 CRITICAL CARE CASE REPORTS: INFECTION AND SEPSIS I 355
D48 CRITICAL CARE CASE REPORTS: INFECTION AND SEPSIS II 356
D49 CRITICAL CARE CASE REPORTS: NEUROCRITICAL CARE, SEDATION, AND DELIRIUM 357
D50 CRITICAL CARE: THE METAMORPHOSIS - PAIN, SEDATION, DELIRIUM, ICU-ACQUIRED WEAKNESS, AND PALLIATIVE CARE 359
D51 CRITICAL CARE: THE FOUNTAINHEAD - FLUIDS, MONITORING AND MANAGEMENT OF SHOCK 360
D52 SMOKING-ASSOCIATED MODIFIERS OF LUNG DISEASE 360
D53 PEDIATRIC ASTHMA CLINICAL STUDIES 361
D54 TO LIVE AND LET DIE: THE ENDOTHELIUM IN PAH 362
D55 CASE REPORTS IN PULMONARY VASCULAR MEDICINE III 363
D56 X MARKS THE SPOT: NEW BIOMARKERS IN PAH 364
D57 ATYPICAL PNEUMONIAS AND OTHER INFECTIONS 365
D58 PLEURAL INFECTION CLINICAL CASE AND STUDIES 366
D59 FUNGAL INFECTION CASE REPORTS 367
D60 PULMONARY FUNCTION AND EXERCISE TESTING AND TRAINING 368
D61 THORACIC ONCOLOGY CASE REPORTS I 369
D62 THORACIC ONCOLOGY CASE REPORTS II 370
D63 THORACIC ONCOLOGY CASE REPORTS III 371
WEDNESDAY MID-DAY, MAY 22 373
WS7 CRISPR: BREAKING BAD FOR THE GOOD OF ADVANCING SCIENCE 373
WS8 PREDICTIVE MODELING IN CRITICAL CARE: PRINCIPLES AND PRACTICE 374
CC5 CRITICAL CARE CLINICAL CORE CURRICULUM I 374
L21 TARGETING OBESE ASTHMA WITHIN THE ALA-ACRC NETWORK 375
L22 ASTHMA PHENOTYPES’ RISK FACTORS AND ROLE OF RESPIRATORY VIRUSES AND BACTERIA IN EXACERBATIONS: LESSONS FROM THE NIAID, NIH INNERCITY ASTHMA CONSORTIUM 375
L23 RESEARCH FUNDING OPPORTUNITIES 375
L24 COMMUNITY BASED INTERVENTIONS IN NHLBI’S ASTHMA EMPOWERMENT COLLABORATIONS TO REDUCE CHILDHOOD ASTHMA DISPARITIES 376
L25 CLINICAL FINDINGS FROM THE NHLBI PVDOMICS PROGRAM IN PATIENTS WITH PULMONARY HYPERTENSION 376
L26 THE MOLECULAR ATLAS OF LUNG DEVELOPMENT (LUNGMAP) 377
WEDNESDAY AFTERNOON, MAY 22 377
CC6 CRITICAL CARE CLINICAL CORE CURRICULUM II 377
D82 AUTOIMMUNE ASSOCIATED ILD: A CASE BASED APPROACH TO DIAGNOSIS AND TREATMENT 378
D83 NEW ADVANCES IN THE BRONCHOSCOPIC DIAGNOSIS AND TREATMENT OF LUNG CANCER 378
D84 REDEFINING ICU SURVIVORSHIP: PREVENTION, RECOVERY AND REINTEGRATION 379
D85 UNFOLDING CIRCADIAN CLOCKS AND ER STRESS IN LUNG DISEASES 380
D86 METABOLISM AS A LINK BETWEEN LUNG CANCER AND ITS MICROENVIRONMENT 380
D87 BEYOND THE RIGHT HEART CATHETERIZATION: QUANTITATIVE METHODS FOR INTERROGATING THE PULMONARY CIRCULATION 381
D88 NEW-TROPHILS: AN OLD CELL WITH NEW TRICKS IN LUNG DISEASE 381
D89 CONTROVERSIES IN PEDIATRIC PULMONOLOGY 382
D90 IMPROVING (LUNG) HEALTH IN PEOPLE LIVING WITH HIV 382
D91 USING THE BASIC BIOLOGY OF IPF TO DESIGN NEW THERAPIES 383
D92 THE MICROBIOME AND LUNG DISEASE 383
D93 PAYING FOR CARE IN PULMONARY DISEASES 384
D94 COPD: EPIDEMIOLOGY AND THERAPY 384
D95 CRITICAL CARE: ALL’S WELL THAT ENDS WELL - TRANSLATING PRACTICE TO OUTCOMES FOR OUR PATIENTS WITH CRITICAL ILLNESS 385
D96 ENVIRONMENTAL ASTHMA EPIDEMIOLOGY 385
D97 FUNGAL INFECTIONS: FROM BENCH TO BEDSIDE 385
D98 NEW MECHANISMS OF ACUTE LUNG INJURY 386
D99 SRN: A LOOK TO THE FUTURE OF SLEEP. USE OF NOVEL TECHNOLOGIES AND SOFTWARE ANALYSIS 386
D101 CLINICAL AND TRANSLATIONAL STUDIES IN ASTHMA AND COPD 387
D102 OPTIMIZING OUTCOMES IN COPD 388
D103 IDIOPATHIC INTERSTITIAL PNEUMONIAS: NATURAL HISTORY AND PROGNOSIS 389
D104 CRITICAL CARE: A FINE BALANCE - SEPSIS DEFINITIONS, OUTCOMES AND EPIDEMIOLOGY 390
D105 IMPROVING PEDIATRIC ASTHMA CONTROL AND OUTCOMES 391
D106 PICK YOUR POISON: GENES, DRUGS, AND PAH 392
D107 MITOCHONDRIA AND ER STRESS IN HOMEOSTASIS AND REPAIR 393
D108 MECHANISM OF LUNG INJURY 394
D109 SRN: OUTCOMES AND IMPACT OF SLEEP AND RESPIRATORY DISORDERS 395
D110 LUNG CANCER: OPTIMIZING SCREENING, DIAGNOSIS, AND TREATMENT 397
BACK COVER 399

RkJQdWJsaXNoZXIy MTM1ODMw